Risk Management



Several New and Revised Consent Forms Published by OMIC

Several new and revised informed consent documents and risk management recommendations documents were recently uploaded.

CATARACT SURGERY

  • New: Same Day Sequential Bilateral Surgery Addendum
  • New: Femtosecond Laser Cataract Surgery Addendum

RETINA

  • New: Intravitreal Anti-VEGF Injections for Adults: Risk Management Recommendations
  • Revised: AvastinTM (bevacizumab) Consent
  • Revised: EyleaTM (aflibercept) Consent
  • Revised: LucentisTM (ranibizumab) Consent
  • Revised: OzurdexTM (dexamethasone) Consent

RETINOPATHY OF PREMATURITY

  • New: Intravitreal Anti-VEGF Injections for ROP: Risk Management Recommendations
  • Revised: Intravitreal Anti-VEGF Injections for ROP Consent

See all new consent forms here.

See all new risk management recommendation guides here.

OMIC policyholders who adminster intravitreal anti-VEGF (IVAV) injections for ROP are strongly encouraged to review these forms and contact OMIC Risk Manager Anne M. Menke, RN, PhD, if you use IVAV for indications not listed on the consent form, or if you have any questions about ROP. She may be reached at 1.800.562-6642, extension 651 or amenke@omic.com.

Please refer to OMIC's Copyright and Disclaimer regarding the contents on this website

Leave a comment



ribbon

Six reasons OMIC is the best choice for ophthalmologists in America.

#2. Leader in the industry.

A-rated by AM Best, OMIC is ranked #1 among 50 malpractice insurance companies in America for financial stability. No other carrier has matched OMIC's consistent financial performance with regard to both combined and operating ratios, the two most relevant financial measurements for an insurance carrier.

61864684